

510(k) SUMMARY AS REQUIRED BY SECTION 807.92(c)

Submitted by:

Irvine Scientific Sales Co., Inc.
2511 Daimler Street
Santa Ana, CA 92705-5588

Telephone: (800) 437-5706
Facsimile: (949) 261-6522

Contact: Wendell Lee, Pharm. D.

Date Submitted: June 15, 2001

Device Identification:

Trade Name: Oil for Embryo Culture
Common Name: Oil for Embryo Culture
Classification Name: Reproductive Media (21 CFR 884.6180)

Predicate Device:

Notice of Final Rule, 63 FR 48428, Docket number 97N-0335

Description:

Oil for Embryo Culture is a solution intended for use in assisted reproductive technology procedures as an overlay to cover small volumes of culture media during embryo and gamete manipulation.

Intended Use:

Oil for Embryo Culture is intended for use in as an overlay to cover small volumes of culture media during embryo and gamete manipulation.

Technological Characteristics:

Oil for Embryo Culture is primarily used as an accessory solution to in an overlay medium to support in vitro fertilization and post fertilization embryo growth. The embryo is allowed to grow in the solution until the desired state of development is reached.

Performance Data:

Oil for Embryo Culture is assayed by mouse embryo assay prior to its release to market. This assay assures that the product will support embryonic growth and that no toxic components are present.

Additional Information:

Mouse embryo, endotoxin and sterility testing will be performed as a condition of release for this product. Results of all release assays performed will be indicated on the labeling and reported on a lot-specific certificate of analysis.

Conclusion:

The conclusion from performance testing as well as a review of the historical information contained in professional literature shows that Oil for Embryo Culture is suitable for the intended use and meets the criteria outlined in the Notice of Final Rule, 63 FR 48428, Docket number 97N-0335.



JUL 1 8 2001

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Wendell Lee, Pharm. D.
Vice President, Quality Systems and Regulatory Affairs
IRVINE SCIENTIFIC
2511 Daimler Street
SANTA ANA CA 92705-5588

Re: K011938
OIL FOR EMBRYO CULTURE
Dated: June 15, 2001
Received: June 21, 2001
Regulatory Class: II
21 CFR 884.6180/Procode: 85 MQL

Dear Dr. Lee:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure (s)

